Skip to main content
CG Oncology, Inc. (CGON)
NASDAQ: CGON · IEX Real-Time Price · USD
35.22
-1.50 (-4.08%)
At close: Jul 19, 2024, 4:00 PM
35.23
+0.01 (0.03%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

CG Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
 TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021
Revenue
-0.20.1910.36
Revenue Growth (YoY)
-6.81%-98.16%-
Gross Profit
-0.20.1910.36
Selling, General & Admin
-9.96.414.65
Research & Development
-45.7529.0318.32
Operating Expenses
-55.6535.4422.96
Operating Income
--55.45-35.25-12.61
Interest Expense / Income
--6.900.45
Other Expense / Income
-0.060.2-0.22
Pretax Income
--48.61-35.44-12.84
Net Income
--48.61-35.44-12.84
Preferred Dividends
-19.198.355.54
Net Income Common
--67.8-43.79-18.38
Shares Outstanding (Basic)
47444
Shares Outstanding (Diluted)
-444
Shares Change
1158.12%15.77%2.47%-
EPS (Basic)
--15.65-11.71-5.04
EPS (Diluted)
--15.65-11.71-5.04
Free Cash Flow
--45.68-29.82-13.75
Free Cash Flow Per Share
--10.55-7.97-3.77
Gross Margin
-100.00%100.00%100.00%
Operating Margin
--27180.88%-18453.40%-121.70%
Profit Margin
--33234.31%-22925.65%-177.48%
Free Cash Flow Margin
--22391.67%-15611.52%-132.76%
EBITDA
--55.48-35.41-12.38
EBITDA Margin
--27197.06%-18539.27%-119.47%
Depreciation & Amortization
-0.030.030.01
EBIT
--55.51-35.44-12.39
EBIT Margin
--27211.27%-18556.02%-119.60%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).